FDA Approves Clinical Trial for Ampion Biologic
Fifteen patients are currently being tested, and the first run-in portion of the trail will evaluate two doses of Ampion in 320 adults with moderate to severe osteoarthritis of the knee.
Once the trial concludes, Ampio will be able to apply for a biologic license application.
Ampion is a non-steroidal anti-inflammatory biologic with many orthopedic applications, according to the release.
More Articles on Supply Chain:
Stryker Unveiled Iconix All Suture Device for Shoulder, Hip Arthroscopy
Biomaterials Market Estimated at $88.4B by 2017
AxioMed Spine Receives Patent for Trapezoidal Disc Replacement Implant
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New from Becker's ASC Review